Key result
Recombinant apoA-I Milano drives rapid regression of coronary atherosclerosis in early evidence.
Answers are grounded in this paper and cite their sources.
INTRODUCTION: Increasing attention has focused on the role of high-density lipoprotein function as a target for cardiprotection. Apolipoprotein A-I(Milano) (AIM) involves a single amino-acid mutation of the major wild-type protein carried on high-density lipoprotein (HDL) particles. Early evidence of beneficial activities of AIM has stimulated support in its development as a potential therapy to reduce cardiovascular risk. AREAS COVERED: The importance of HDL as a target and early data supporting the beneficial effects of AIM are reviewed. All clinical studies of AIM found in PubMed are reviewed. EXPERT OPINION: ETC-216 represents a lipid-deplete form of HDL containing recombinant AIM. While early evidence suggests that administration of ETC-216 promotes rapid regression of coronary atherosclerosis, bringing this compound to clinical practice will require further trials that evaluate its impact on cardiovascular events.
No takes yet. Share an insight, caveat, or question.
Nicholls et al. (2011) conducted a review in Coronary artery disease / coronary atherosclerosis. ETC-216 (recombinant Apolipoprotein A-I Milano) was evaluated on Regression of coronary atherosclerosis. ETC-216 (recombinant apolipoprotein A-I Milano) promotes rapid regression of coronary atherosclerosis in early evidence, though clinical event trials are needed.
Synapse has enriched 10 related papers. Consider them for comparative context: